395-47-1Relevant academic research and scientific papers
Nickel-Catalyzed Cross-Coupling of Functionalized Organo manganese Reagents with Aryl and Heteroaryl Halides Promoted by 4-Fluorostyrene
Benischke, Andreas D.,Desaintjean, Alexandre,Juli, Thomas,Cahiez, Gérard,Knochel, Paul
supporting information, p. 5396 - 5412 (2017/12/14)
A catalytic system consisting of Ni(acac) 2 (5 mol%) and 4-fluorostyrene (20 mol%) allows a convenient cross-coupling of functionalized organomanganese reagents with a variety of aryl and heteroaryl halides leading to polyfunctionalized diaryl- and arylheteroarylmethane derivatives.
Preparation of Trifluoromethylphenyl Magnesium Halides in the Presence of LiCl and Synthesis of 2′-Trifluoromethyl-Aromatic Ketones
Nakatani, Jiro,Nozoe, Tatsuhiro
, p. 1633 - 1636 (2016/09/23)
The effect of LiCl-promoted insertion of magnesium turnings into halogenated-trifluoromethylbenzenes for Grignard reagent synthesis was investigated. In the presence of less than 1.0 equiv of LiCl, chloro(trifluoromethyl)benzene Grignard reagents were easily generated. The 2-trifluoromethylphenyl magnesium chloride Grignard reagent was obtained in high yield and 2′-trifluoromethyl-substituted aromatic ketone was synthesized through reaction of the obtained Grignard reagent with a carboxylic anhydride in an 83% yield.
Formation of 2-trifluoromethylphenyl grignard reagent via magnesium-halogen exchange: Process safety evaluation and concentration effect
Tang, Wenjun,Sarvestani, Max,Wei, Xudong,Nummy, Laurence J.,Patel, Nitinchandra,Narayanan, Bikshandarkoil,Byrne, Denis,Lee, Heewon,Yee, Nathan K.,Senanayake, Chris H.
experimental part, p. 1426 - 1430 (2010/04/22)
The thermal stability profile for a solution of 2-trifluoromethylphenyl magnesium chloride at 1.5Mconcentration in THF was determined using an Advanced Reactive System Screening Tool (ARSST). The solution generated by employing Knochel's magnesium-halogen
AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS
-
Page 52, (2008/06/13)
Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CB1 receptors such as obesity: Formuila (I) wherein: R1 and R2 are independently selected from aryl; and R3 is hydrogen or alkyl; or a pharmaceutically acceptable salt or prodrug thereof, wherein at least one of R1 and R2 has a non-hydrogen substituent in the ortho-position(s) thereof relative to the point of attachment to the [-CH-0-] group.
